News
Important Only
Automakers could still face $2,000 to $12,000 vehicle price impacts from tariffs
WASHINGTON, May 1 (Reuters) - A Michigan-based economic consulting group said Thursday that automakers will still face $2,000 to $12,000 price impacts despite softened auto parts tariffs imposed by the White House and retaliatory tariffs.Anderson Economic Group said U.S. assembled vehicles like Hond...Reuters
Thu, May 1
BREAKINGVIEWS-GM’s financial auguries echo beyond Wall Street
By Jonathan Guilford NEW YORK, May 1 (Reuters Breakingviews) - General Motors GM.N is taking its financial show on the road. The $44 billion automaker released updated estimates for full-year financial results on Thursday, after scrapping previous guesses undermined by President Donald Trump’s t...Reuters
Thu, May 1
BREAKINGVIEWS-FDIC’s living-will rewrite haunted by ghost of SVB
By Stephen GandelNEW YORK, May 1 (Reuters Breakingviews) - A top U.S. bank regulator wants to make it simpler for troubled lenders to give up the ghost. The Federal Deposit Insurance Corporation announced changes to living wills, documents maintained by roughly 50 of the largest banks spelling out h...Reuters
Thu, May 1
Cardinal Health expects double-digit growth in fiscal 2026 despite tariff hit
By Kamal Choudhury May 1 (Reuters) - Cardinal Health CAH.N forecast double-digit growth in earnings for the fiscal year 2026, despite a hit of $200 million to $300 million due to extreme tariff rates, the drug distributor said on Thursday. The company sources about 10% of its products...Reuters
Thu, May 1
American Rebel Holdings Aims To Expand Product Line Beyond Beverages
May 1 (Reuters) - American Rebel Holdings Inc AREB.O:AMERICAN REBEL HOLDINGS, INC. (NASDAQ: AREB) HIGHLIGHTS KEY STRATEGIC EXPANSION INITIATIVES FOLLOWING SUCCESSFUL BOARD MEETING AND INVESTOR ENGAGEMENT AT MAR-A-LAGOAMERICAN REBEL HOLDINGS INC - AIMS TO EXPAND PRODUCT LINE BEYOND BEVERAGESReuters
Thu, May 1
Zelenskiy says minerals deal is first result of Vatican meeting with Trump
May 1 (Reuters) - President Volodymyr Zelenskiy on Thursday hailed a minerals deal with the U.S. as a truly equal and fair agreement, and the first result of his Vatican meeting with U.S. President Donald Trump on the sidelines of the funeral of Pope Francis.Zelenskiy said the minerals deal opens th...Reuters
Thu, May 1
South Korea presidential race rocked by court ruling, resignations
Supreme court strikes blow against frontrunner Lee Jae-myungLee led opinion polls despite legal challengesActing president Han resigns ahead of expected presidential bidFinance minister resigns amid impeachment voteEducation minister takes over as new acting president South Korea holds presidential ...Reuters
Thu, May 1
Gol Reaches Settlement With AD HOC Group Of 2026 Noteholders
May 1 (Reuters) - Gol Linhas Aereas Inteligentes SA GOLL4.SA:GOL REACHES SETTLEMENT WITH AD HOC GROUP OF 2026 NOTEHOLDERSGOL LINHAS AEREAS INTELIGENTES SA - AD HOC GROUP COMMITS TO PURCHASE $125 MILLION IN EXIT FINANCINGGOL LINHAS AEREAS INTELIGENTES SA - CASTLELAKE AND ELLIOTT CONSENT TO CHANGES IN...Reuters
Thu, May 1
US politics newsletter - A long 100 days
By Jeff Mason WASHINGTON, May 1 (Reuters) - How many years are there in 100 days? President Donald Trump hit the 100-day milestone of his second term this week, sparking celebration by his supporters and criticism from his detractors, but one thing perhaps both sides can agree on: this felt l...Reuters
Thu, May 1
HHS, NIH launch next-generation universal vaccine platform for pandemic-prone viruses
May 1 (Reuters) - NIH : NIH: HHS, NIH LAUNCH NEXT-GENERATION UNIVERSAL VACCINE PLATFORM FOR PANDEMIC-PRONE VIRUSESNIH: CLINICAL TRIALS FOR UNIVERSAL INFLUENZA VACCINES ARE SCHEDULED TO BEGIN IN 2026NIH: INTRANASAL BPL-1357 FLU VACCINE, CURRENTLY IN ADVANCED TRIALS, IS ALSO ON TRACK FOR FDA REVIEW BY...Reuters
Thu, May 1
Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design
May 1 (Reuters) - Nexalin Technology Inc NXL.O:NEXALIN TECHNOLOGY INITIATES FDA Q-SUBMISSION PROCESS FOR GEN-2 SYNC FOLLOWING ENCOURAGING DATA AND PRELIMINARY FDA FEEDBACKNEXALIN TECHNOLOGY INC - Q-SUBMISSION TO FACILITATE DIALOGUE WITH FDA ON CLINICAL TRIAL DESIGNReuters
Thu, May 1
